Shire Buys Rare Disease Drug Developer

The Irish drugmaker is set to acquire the Massachusetts-based Dyax in a $5.9 billion deal.

By | November 2, 2015

WIKIMEDIA, URCOMUNICACIONThrough its latest acquisition effort, Irish drugmaker Shire is paying approximately $5.9 billion for Massachusetts-based Dyax Corp., a biotech firm focused on a rare disease called hereditary angioedema (HAE). Dyax’s lead candidate, DX-2930, is a fully humanized monoclonal antibody targeting plasma kallikrein, which is dysregulated in HAE. According to a statement from Shire, DX-2930 is expected to enter Phase 3 trials by the end of this year.

“Shire’s expertise and proven rare disease patient identification and management capabilities make it the ideal partner to efficiently bring DX-2930 to HAE patients worldwide,” Gustav Christensen, president and chief executive of Dyax, said in the statement.

This January, Shire paid $5.2 billion for New Jersey-based NPS Pharmaceuticals. In the statement, Shire Chief Executive Officer Flemming Ornskov said his firm is now eyeing other acquisitions, including that of the Illinois-based biopharma Baxalta.

Add a Comment

Avatar of: You

You

Processing...
Processing...

Sign In with your LabX Media Group Passport to leave a comment

Not a member? Register Now!

LabX Media Group Passport Logo

Popular Now

  1. That Other CRISPR Patent Dispute
    Daily News That Other CRISPR Patent Dispute

    The Broad Institute and Rockefeller University disagree over which scientists should be named as inventors on certain patents involving the gene-editing technology.

  2. How Gaining and Losing Weight Affects the Body
    Daily News How Gaining and Losing Weight Affects the Body

    Millions of measurements from 23 people who consumed extra calories every day for a month reveal changes in proteins, metabolites, and gut microbiota that accompany shifts in body mass.

  3. Neurons Use Virus-Like Proteins to Transmit Information
  4. DOE-Sponsored Oak Ridge National Laboratory to Cut 100 More Jobs
AAAS